Edition:
United States

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

24.75USD
10:45am EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$24.75
Open
$24.75
Day's High
$24.80
Day's Low
$24.45
Volume
10,467
Avg. Vol
141,871
52-wk High
$30.35
52-wk Low
$14.95

Latest Key Developments (Source: Significant Developments)

Lannett Appoints Timothy Crew As CEO
Thursday, 21 Dec 2017 06:54am EST 

Dec 21 (Reuters) - Lannett Company Inc ::LANNETT APPOINTS TIMOTHY C. CREW AS CEO.LANNETT COMPANY INC - TIMOTHY CREW WILL SUCCEED ARTHUR BEDROSIAN, WHO WILL CONTINUE TO SERVE AS CEO UNTIL CREW JOINS COMPANY.LANNETT COMPANY INC - BOARD NAMED TIMOTHY C. CREW AS CHIEF EXECUTIVE OFFICER, EFFECTIVE JANUARY 2, 2018.  Full Article

Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution
Friday, 1 Dec 2017 06:53am EST 

Dec 1 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR COCAINE HYDROCHLORIDE TOPICAL SOLUTION, A PROPRIETARY ANESTHETIC PRODUCT.LANNETT COMPANY - ‍FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF JULY 21, 2018, TEN MONTHS FROM OFFICIAL NDA SUBMISSION DATE​.  Full Article

Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL
Wednesday, 29 Nov 2017 04:47pm EST 

Nov 29 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®.LANNETT COMPANY INC - FINANCIAL TERMS WERE NOT DISCLOSED..LANNETT COMPANY INC - HAS ENTERED INTO AN AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC.LANNETT COMPANY - ‍AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF AUTHORIZED GENERIC VERSION OF TOPROL-XL​.LANNETT COMPANY INC - DEAL TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF TOPROL-XL EXTENDED RELEASE TABLETS IN 25 MG, 50 MG, 100 MG AND 200MG.  Full Article

Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance
Monday, 6 Nov 2017 04:15pm EST 

Nov 6 (Reuters) - Lannett Company Inc :Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance.Q1 adjusted earnings per share $0.60.Q1 earnings per share $0.35.Q1 earnings per share view $0.52 -- Thomson Reuters I/B/E/S.Q1 sales $155 million versus I/B/E/S view $153.6 million.Lannett Company Inc sees fiscal 2018 ‍net sales of $710 million to $720 million, up from $655 million to $665 million​.Lannett Company Inc sees fiscal 2018 ‍capital expenditures of $65 million to $75 million.Q1 revenue view $153.6 million -- Thomson Reuters I/B/E/S.FY2018 revenue view $658.6 million -- Thomson Reuters I/B/E/S.  Full Article

Deerfield Management LP reports 8.28% passive stake in Lannett Co as of Oct 25, 2017-SEC filing‍​
Monday, 6 Nov 2017 03:49pm EST 

Nov 6 (Reuters) - Deerfield Management L.P: :Deerfield Management LP reports a 8.28 percent passive stake in Lannett Company Inc as of October 25, 2017-SEC filing‍​.  Full Article

Lannett Co calls price fixing allegations about a single product named in complaint that co sells "meritless"
Wednesday, 1 Nov 2017 06:53am EDT 

Nov 1 (Reuters) - Lannett Company Inc :Lannett Company Inc - ‍comments on amended civil generic drug price-fixing complaint ​.Lannett - believe price-fixing allegations about a single product named in complaint that co sells are "meritless​".  Full Article

Lannett and Celgene enter into settlement and license agreement related to Thalomid
Monday, 30 Oct 2017 06:52am EDT 

Oct 30 (Reuters) - Celgene Corp :Lannett and Celgene enter into settlement and license agreement related to Thalomid.Lannett - ‍subject to FDA approval of co's ANDA for thalidomide, co intends to launch product under terms of license agreement, which are confidential​.Lannett-‍license agreement permits co to manufacture, market in U.S. generic thalidomide product as of Aug 1, 2019 or earlier under certain circumstances​.  Full Article

Lannett receives two FDA approvals for Lansoprazole, one each for full prescription and OTC
Monday, 2 Oct 2017 06:56am EDT 

Oct 2 (Reuters) - Lannett Company Inc : :Lannett receives two fda approvals for Lansoprazole delayed-release capsules usp, one each for full prescription and OTC.Lannett Company Inc - co expect to commence marketing our prescription Lansoprazole delayed-release capsules product in next several months​.  Full Article

Lannett receives FDA approval for Oxycodone and Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg
Wednesday, 27 Sep 2017 06:51am EDT 

Sept 27 (Reuters) - Lannett Company Inc :Lannett receives FDA approval for Oxycodone And Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg.Lannett Company Inc - ‍Expect to commence marketing drug along with other approved products in next several months​.  Full Article

Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg
Tuesday, 26 Sep 2017 06:53am EDT 

Sept 26 (Reuters) - Lannett Company Inc :Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg.Lannett Company Inc - ‍Anticipates launching Dexmethylphenidate Hydrochloride tablets in next several months​.Lannett Company Inc - ‍Dexmethylphenidate Hydrochloride tablets are used for treatment of attention deficit and hyperactivity disorder ​.  Full Article

BRIEF-Lannett Appoints Timothy Crew As CEO

* LANNETT COMPANY INC - TIMOTHY CREW WILL SUCCEED ARTHUR BEDROSIAN, WHO WILL CONTINUE TO SERVE AS CEO UNTIL CREW JOINS COMPANY